Uric Acid and Diabetic Nephropathy Risk

Area of Science:

• Nephrology
• Endocrinology
• Clinical Trials

Background:

• Diabetic nephropathy (DN) is the primary cause of end-stage renal disease (ESRD), with current treatments showing limited impact on new ESRD cases.
• Elevated serum uric acid (UA) is linked to DN risk and progression, indicating a potential therapeutic target.
• Previous small trials suggest UA reduction may benefit chronic kidney disease (CKD) but definitive evidence in DN is lacking.

Purpose of the Study:

• To evaluate if reducing serum uric acid (UA) with allopurinol can slow the decline in glomerular filtration rate (GFR) in patients with type 1 diabetes and early to moderate DN.
• To determine if UA reduction can offer a significant benefit in delaying ESRD compared to current therapies like renin-angiotensin system blockade (RASB).

Main Methods:

• The Preventing Early Renal Loss in Diabetes (PERL) trial is a 3-year, randomized, placebo-controlled study involving 530 subjects.
• Participants have type 1 diabetes with early to moderate GFR reduction.
• The primary endpoint is the rate of GFR decline, measured by the plasma disappearance of iohexol.

Main Results:

• The PERL trial is ongoing; definitive results are pending.
• Key Message: Positive results could indicate that UA reduction, initiated early, may delay ESRD in DN by 8-10 years.

Conclusions:

• If the PERL trial confirms its hypothesis, UA reduction could become a crucial therapeutic strategy for DN and CKD.
• This approach may offer a more substantial benefit in delaying ESRD than current standard treatments.